Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net sales	$ 647,263	$ 560,633	$ 1,755,787	$ 1,687,231
Cost of goods sold	279,952	253,607	778,120	760,674
Gross profit	367,311	307,026	977,667	926,557
Selling, general and administrative expense	198,165	201,622	581,119	610,460
Research and Development Expense	59,546	47,944	160,833	145,641
Segment profit (loss)	109,600	57,460	235,715	170,456
Interest expense	5,728	5,525	17,158	17,352
Foreign exchange (gains) losses, net	776	898	2,478	3,411
Marketable Securities, Unrealized (Gain) Loss	(1,580,350)	390,620	(3,591,509)	(1,384,999)
Other Nonoperating Income (Expense)	1,015	4,367	21,517	26,959
Income before income taxes	1,684,461	(335,216)	3,829,105	1,561,651
(Provision) benefit for income taxes	(369,637)	76,400	(861,940)	(356,462)
Net income attributable to Bio-Rad	$ 1,314,824	$ (258,816)	$ 2,967,165	$ 1,205,189
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 44.24	$ (8.68)	$ 99.75	$ 40.42
Weighted average common shares - basic	29,721	29,831	29,746	29,815
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 43.64	$ (8.68)	$ 98.46	$ 39.97
Weighted average common shares - diluted	30,128	29,831	30,137	30,149